EUCTR2020-003372-41-IT进行中（未招募）1 期
Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa via the DopaFuse® Delivery System in Parkinson’s Disease Patients - Study of Continuous Oral Levodopa: SCO
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Diagnosis of Parkinson's Disease consistent with UK Brain Bank Criteria
- •2. Age at least 30 years old at time of consent
- •3. Male and Female participants (Women of child-bearing potential (WOCB) are eligible for participation if they are not pregnant or breastfeeding and agree to follow the contraceptive guidance in Appendix 3 during the treatment period and for at least 30 days after the last dose of study treatment)
- •4. Suitable for oral retainer wear
- •5. A good response to Levodopa, as assessed by the Investigator
- •6. At least 2 hours of wearing OFF time per day, as reported by the
- •participant
- •7. Predictable early morning OFF periods, in the judgement of the participant and the Investigator
- •8. Taking 400-1,200 mg of LD/CD per day in at least 4 doses, with stable dosing for the last 28 days prior to screening.
- •9. A modified Hoehn and Yahr of ¿ 3 in the ON state at screening
- •10. A stable regimen of anti-PD medications for the last 28 days prior to Screening
- •11. A Mini-Mental State Examination (MMSE) Score =26
- •12. Capable of giving signed informed consent Approved for entry into the study by the Enrollment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 14
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Atypical or secondary Parkinson's Disease
- •2. Severe Dyskinesia that might interfere with study performance in the judgement of Investigator
- •3. Clinically significant dysphagia or sialorrhea that might interfere with administration of study intervention in the judgement of the Investigator
- •4. Use of extended release levodopa within 28 days prior to screening
- •5. Any clinically significant medical, surgical, or psychiatric condition; laboratory value or ECG result which, in the opinion of the Investigator, makes the participant unsuitable for study entry or potentially unable to complete all aspects of the study.
- •6. Presence of clinically significant orthostatic hypotension at screening, in the opinion of Investigator or the EAC
- •7. Suicidal ideation within 1 year prior to the Screening Visit as evidenced by answering yes to Questions 4 or 5 on the suicidal ideation portion of the Columbia Suicide Severity Rating Scale (C-SSRS) or attempted suicide within the last 5 years.
- •8. History of psychosis or hallucinations in the past six months
- •9. Any malignancy in the past 5 years (excluding basal cell carcinoma of the skin or cervical carcinoma in situ that have been successfully treated.)
- •10. Current or previous diagnosis of malignant melanoma or the presence of any suspicious skin lesion based on physical exam findings
- •11. Unable to give blood required for the study
- •12. History of allergic reaction to plastics
- •13. LD infusion therapy (i.e. Duodopa); current or previous continuous apomorphine infusion treatment.
- •14. Participation in any other clinical trial <30 days prior to screening visit.
- •15. Presence of two third molars (wisdom teeth) on the upper dentition
- •16. Participants who, for any reason, are judged by the Investigator or the EAC to be inappropriate for this study, including participants who are unable to communicate or cooperate with the Investigator or who have/had a clinically significant illness or abnormal physical examination that may compromise safety of the participant during the trial or affect ability of the participant to adhere to study procedures.
- •17. Participants taking non-selective monoamine oxidase (MAO) inhibitors
- •18. Participants with known hypersensitivity to the active ingredients (levodopa, carbidopa) or excipients (Benzoic Acid, Disodium Edetate, Medium Chain Triglycerides, Poloxamer 188) of the drug paste
- •19. Participants with narrow-angle glaucoma
研究者
相似试验
进行中（未招募）
1 期
Investigating the DopaFuse® Delivery System in Parkinson’s Disease Patients. Assessing safety, effectiveness, how well it is tolerated, and how the drug is processed by the body.Motor symptoms in Parkinson’s Disease.MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-003372-41-ESSynAgile Corporation24
进行中（未招募）
1 期
Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV)in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-Positive. Revised Protocol 02, incorporating Protocol Amendment 01 (v1.0, date 18-Apr-2008), and Protocol Amendment 04 (v1.0, date 05-Dec-2008).Chronic Hepatitis B Virus (HBV) InfectionMedDRA version: 8.1Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)EUCTR2005-005816-26-BEBristol-Myers Squibb International Corporation64
进行中（未招募）
1 期
A study of Entecavir in Pediatric Patients with Chronic Hepatitis B Virus (HBV) InfectioChronic Hepatitis B Virus (HBV) InfectionMedDRA version: 16.1 Level: LLT Classification code 10019743 Term: Hepatitis B virus (HBV) System Organ Class: 100000004848EUCTR2005-005816-26-GBBristol-Myers Squibb International Corporation64
进行中（未招募）
不适用
A study of Entecavir in Pediatric Patients with Chronic Hepatitis B Virus (HBV) InfectioEUCTR2005-005816-26-Outside-EU/EEABristol-Myers Squibb International Corporation64
尚未招募
1 期
Phase 1a study of VGA039 in healthy volunteers and patients with von Willebrand diseaseCTRI/2024/04/065934Vega Therapeutics, Inc